<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ssmu</journal-id><journal-title-group><journal-title xml:lang="ru">Бюллетень сибирской медицины</journal-title><trans-title-group xml:lang="en"><trans-title>Bulletin of Siberian Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1682-0363</issn><issn pub-type="epub">1819-3684</issn><publisher><publisher-name>Siberian State Medical University, the Ministry of Healthcare of the Russian Federation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20538/1682-0363-2023-1-23-32</article-id><article-id custom-type="elpub" pub-id-type="custom">ssmu-5128</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL PAPERS</subject></subj-group></article-categories><title-group><article-title>Экстракт из культуры термофильного штамма Staphylococcus aureus подавляет аллергическое воспаление в дыхательных путях in vivo и дегрануляцию тучных клеток и базофилов in vitro</article-title><trans-title-group xml:lang="en"><trans-title>An extract from the culture of a thermophilic Staphylococcus aureus strain suppresses allergic inflammation in the airways in vivo and degranulation of mast cells and basophils in vitro</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3628-2436</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Калюжин</surname><given-names>О. B.</given-names></name><name name-style="western" xml:lang="en"><surname>Kalyuzhin</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Калюжин Олег Витальевич – доктор медицинских наук, профессор, кафедра клинической иммунологии и аллергологии</p><p>119991, г. Москва, ул. Трубецкая, 8/2</p></bio><bio xml:lang="en"><p>8/2, Trubetskaya Str., Moscow, 119991</p></bio><email xlink:type="simple">kalyuzhin@list.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5718-3301</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Проскурина</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Proskurina</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Проскурина Оксана Владимировна – кандидат медицинских наук</p><p>142450, г. Старая Купавна, ул. Кирова, 23</p></bio><bio xml:lang="en"><p>23, Kirova Str., Staraya Kupavna, 142450</p></bio><email xlink:type="simple">proskurina_ov@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0548-4249</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Суханова</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Sukhanova</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Суханова Светлана Алексеевна – кандидат биологических наук</p><p>142450, г. Старая Купавна, ул. Кирова, 23</p></bio><bio xml:lang="en"><p>23, Kirova Str., Staraya Kupavna, 142450</p></bio><email xlink:type="simple">ssuhanova@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Новикова</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Novikova</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Новикова Наталья Викторовна – врач высшей категории, аллерголог-иммунолог</p><p>123104, г. Москва, ул. Малая Бронная, 20/1</p></bio><bio xml:lang="en"><p>20/1, Malaya Bronnaya Str., Moscow, 123104</p></bio><email xlink:type="simple">doctor.novikova@gmail.com</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6891-3250</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Колганова</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kolganova</surname><given-names>N. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Колганова Нина Алексеевна – доктор медицинских наук, профессор, кафедра госпитальной терапии</p><p>117997, г. Москва, ул. Островитянова, 1</p></bio><bio xml:lang="en"><p>1, Ostrovityanova Str., Moscow, 117997</p></bio><email xlink:type="simple">nina3580@yandex.ru</email><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Первый Московский государственный медицинский университет им. И.М. Сеченова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I.M. Sechenov First Moscow State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Всероссийский научный центр по безопасности биологически активных веществ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>All-Russian Scientific Center for the Safety of Biologically Active Substances</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Институт аллергологии и клинической иммунологии</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Institute of Allergy and Clinical Immunology</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>Российский национальный исследовательский медицинский университет им. Н.И. Пирогова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N.I. Pirogov Russian National Research Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>19</day><month>04</month><year>2023</year></pub-date><volume>22</volume><issue>1</issue><fpage>23</fpage><lpage>32</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Калюжин О.B., Проскурина О.В., Суханова С.А., Новикова Н.В., Колганова Н.А., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Калюжин О.B., Проскурина О.В., Суханова С.А., Новикова Н.В., Колганова Н.А.</copyright-holder><copyright-holder xml:lang="en">Kalyuzhin O.V., Proskurina O.V., Sukhanova S.A., Novikova N.V., Kolganova N.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://bulletin.ssmu.ru/jour/article/view/5128">https://bulletin.ssmu.ru/jour/article/view/5128</self-uri><abstract><p>Цель – изучить противоаллергическое действие рузама – экстракта из культуры термофильного штамма Staphylococcus aureus – на модели астмы in vivo, а также его влияние на дегрануляцию тучных клеток и базофилов in vitro.</p><sec><title>Материалы и методы</title><p>Материалы и методы. Аллергическую астму у морских свинок воспроизводили двумя внутрибрюшинными инъекциями овальбумина с последующей серией ингаляций этого антигена в течение 1,5 мес. Рузам (6 мкг/кг) или референс-препарат (кромогликат натрия, 3 мг/кг) вводили ежедневно с помощью небулайзера в течение последних 6 сут иммунизации. Через 1 сут после завершения ингаляций овальбумина и сравниваемых препаратов оценивали изменения в дыхательных путях с помощью цитологических, морфометрических и гистологических методов. Для определения влияния рузама на IgE-независимую дегрануляцию, индуцированную соединением 48/80 in vitro, использовали базофилы крови кроликов и перитонеальные тучные клетки крыс. Эффект рузама сравнивали с таковым гидрокортизона гемисукцината. Базофилы крови сенсибилизированных овальбумином морских свинок использовали при оценке действия препарата на IgE-зависимую дегрануляцию, индуцированную овальбумином. Гранулы тучных клеток и базофилов для расчета индекса дегрануляции окрашивали с помощью альцианового синего.</p></sec><sec><title>Результаты</title><p>Результаты. На модели астмы рузам снижал степень обструкции дыхательных путей, повышая объем возврата бронхоальвеолярного смыва, и подавлял нейтрофильное и эозинофильное воспаление, при этом мобилизуя другие клетки-эффекторы противоинфекционного ответа (лимфоциты и макрофаги). По ряду критериев противоаллергической эффективности рузам превосходил кромогликат натрия. Рузам в концентрациях 8,4–840 мкг/мл ингибировал дегрануляцию тучных клеток и базофилов, вызванную соединением 48/80, в той же степени, что и гидрокортизона гемисукцинат (10–3 М). Рузам (280 и 420 мкг/мл) дозозависимо подавлял индуцированную овальбумином дегрануляцию базофилов сенсибилизированных морских свинок.</p></sec><sec><title>Заключение</title><p>Заключение. Подтверждено противоаллергическое действие рузама в тест-системах in vivo и in vitro. Выдвинута гипотеза о TLR2-опосредованном характере биологических/фармакологических эффектов препарата.</p></sec><sec><title> </title><p> </p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To study the anti-allergic effects of ruzam, an extract from the culture of a thermophilic Staphylococcus aureus strain, in an in vivo model of asthma and its influence on degranulation of mast cells and basophils in vitro.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. Allergic asthma in guinea pigs was reproduced by two intraperitoneal injections of ovalbumin followed by a series of inhalations of this antigen for 1.5 months. Ruzam (6 μg / kg) or a reference drug (sodium cromoglycate, 3 mg / kg) was administered daily via a nebulizer during the last 6 days of immunization. One day after completion of inhalations with ovalbumin and compared drugs, changes in the airways were assessed using cytological, morphometric, and histologic methods. Rabbit blood basophils and rat peritoneal mast cells were used to determine the effect of ruzam on IgE-independent degranulation induced by the compound 48 / 80 in vitro. The effect of ruzam was compared with that of hydrocortisone hemisuccinate. Basophils from the blood of ovalbumin-sensitized guinea pigs were used to evaluate the effect of the drug on IgE-dependent degranulation induced by ovalbumin. Granules of mast cells and basophils were detected by alcian blue staining to calculate the degranulation index.</p></sec><sec><title>Results</title><p>Results. In the asthma model, ruzam reduced the degree of airway obstruction by increasing the bronchoalveolar lavage volume returned and suppressed neutrophilic and eosinophilic inflammation, while mobilizing other effector cells of the anti-pathogen immunity (lymphocytes and macrophages). Ruzam has proven to have a stronger anti-allergic effect than sodium cromoglycate by several parameters. At concentrations of 8.4–840 μg / ml, ruzam inhibited degranulation of mast cells and basophils, induced by the compound 48 / 80, equally to hydrocortisone hemisuccinate (10–3 M). At concentrations of 280 and 420 μg / ml, ruzam dose-dependently inhibited ovalbumin-induced degranulation of basophils in sensitized guinea pigs.</p></sec><sec><title>Conclusion</title><p>Conclusion. The anti-allergic effect of ruzam was confirmed in test systems in vivo and in vitro. We speculate here that the TLR2 signaling pathway may be involved in biological and pharmacological effects of this drug.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>рузам</kwd><kwd>Staphylococcus aureus</kwd><kwd>термофильный штамм</kwd><kwd>модель астмы</kwd><kwd>аллергическое воспаление</kwd><kwd>тучные клетки</kwd><kwd>базофилы</kwd><kwd>дегрануляция</kwd></kwd-group><kwd-group xml:lang="en"><kwd>ruzam</kwd><kwd>Staphylococcus aureus</kwd><kwd>thermophilic strain</kwd><kwd>asthma model</kwd><kwd>allergic inflammation</kwd><kwd>mast cells</kwd><kwd>basophils</kwd><kwd>degranulation</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Chedid L., Audibert F. Chemically defined bacterial products with immunopotentiating activity. J Infect Dis. 1977;136(Suppl.):S246–S251. DOI: 10.1093/infdis/136.supplement.s246.</mixed-citation><mixed-citation xml:lang="en">Chedid L., Audibert F. Chemically defined bacterial products with immunopotentiating activity. J Infect Dis. 1977;136(Suppl.):S246–S251. DOI: 10.1093/infdis/136.supplement.s246.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Le Garrec Y. Immunomodifiers of bacterial origin. Comp. Immunol. Microbiol. Infect. Dis. 1986;9(2–3):137–141. DOI: 10.1016/0147-9571(86)90005-6.</mixed-citation><mixed-citation xml:lang="en">Le Garrec Y. Immunomodifiers of bacterial origin. Comp. Immunol. Microbiol. Infect. Dis. 1986;9(2–3):137–141. DOI: 10.1016/0147-9571(86)90005-6.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Пронин А.В., Санин А.В., Гинцбург А.Л. Бактериальные иммуномодуляторы и их место в иммуномодулирующей терапии. В кн.: Иммунотерапия. Руководство для врачей; под ред. Р.М. Хаитова, Р.И. Атауллаханова, А.Е. Шульженко. М.: ГЭОТАР-Медиа, 2000:191–212.</mixed-citation><mixed-citation xml:lang="en">Пронин А.В., Санин А.В., Гинцбург А.Л. Бактериальные иммуномодуляторы и их место в иммуномодулирующей терапии. В кн.: Иммунотерапия. Руководство для врачей; под ред. Р.М. Хаитова, Р.И. Атауллаханова, А.Е. Шульженко. М.: ГЭОТАР-Медиа, 2000:191–212.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Терехова Е.П., Терехов Д.В., Себекина О.В. Применение препарата Рузам® в лечении и профилактике аллергических заболеваний. Практическая аллергология. 2021;1:54– 64. DOI: 10.46393/2712-9667_2021_1_54-64.</mixed-citation><mixed-citation xml:lang="en">Терехова Е.П., Терехов Д.В., Себекина О.В. Применение препарата Рузам® в лечении и профилактике аллергических заболеваний. Практическая аллергология. 2021;1:54– 64. DOI: 10.46393/2712-9667_2021_1_54-64.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Чучалин А.Г., Ковалева В., Колганова Н.А. Рузам – новый подход в лечении и профилактике аллергических заболеваний (экспериментальные и клинические данные). Русский медицинский журнал. 2003;11(22):1248–1252.</mixed-citation><mixed-citation xml:lang="en">Чучалин А.Г., Ковалева В., Колганова Н.А. Рузам – новый подход в лечении и профилактике аллергических заболеваний (экспериментальные и клинические данные). Русский медицинский журнал. 2003;11(22):1248–1252.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Ненашева Н.М., Терехова Е.П., Терехов Д.В. Эффективность ингаляционной иммунотерапии Рузамом у больных атопической бронхиальной астмой: влияние на частоту респираторных инфекций и обострений. Пульмонология. 2014;1:52–58. DOI: 10.18093/0869-0189-2014-0-1-52-58.</mixed-citation><mixed-citation xml:lang="en">Ненашева Н.М., Терехова Е.П., Терехов Д.В. Эффективность ингаляционной иммунотерапии Рузамом у больных атопической бронхиальной астмой: влияние на частоту респираторных инфекций и обострений. Пульмонология. 2014;1:52–58. DOI: 10.18093/0869-0189-2014-0-1-52-58.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Hutson P.A., Church M.K., Clay T.P., Miller P., Holgate S.T. Early and late-phase bronchoconstriction after allergen challenge of nonanesthetized guinea pigs. I. The association of disordered airway physiology to leukocyte infiltration. Am. Rev. Respir. Dis. 1988;137(3):548–557. DOI: 10.1164/ajrccm/137.3.548.</mixed-citation><mixed-citation xml:lang="en">Hutson P.A., Church M.K., Clay T.P., Miller P., Holgate S.T. Early and late-phase bronchoconstriction after allergen challenge of nonanesthetized guinea pigs. I. The association of disordered airway physiology to leukocyte infiltration. Am. Rev. Respir. Dis. 1988;137(3):548–557. DOI: 10.1164/ajrccm/137.3.548.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Ковалева В.Л. Методические указания по изучению фармакологических веществ, предназначенных для терапии бронхиальной астмы и других обструктивных заболеваний дыхательных путей. В кн.: Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ: 2-е изд.; под ред. Р.У. Хабриева. М.: Медицина, 2005:483–500.</mixed-citation><mixed-citation xml:lang="en">Ковалева В.Л. Методические указания по изучению фармакологических веществ, предназначенных для терапии бронхиальной астмы и других обструктивных заболеваний дыхательных путей. В кн.: Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ: 2-е изд.; под ред. Р.У. Хабриева. М.: Медицина, 2005:483–500.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Nagai H., Tsuji F., Goto S., Koda A. Pharmacological modulation of antigen-induced airway hyperresponsiveness by thromboxane A2 inhibitors in guinea pigs. Biol. Pharm. Bull. 1993;16(11):1099–1103. DOI: 10.1248/bpb.16.1099.</mixed-citation><mixed-citation xml:lang="en">Nagai H., Tsuji F., Goto S., Koda A. Pharmacological modulation of antigen-induced airway hyperresponsiveness by thromboxane A2 inhibitors in guinea pigs. Biol. Pharm. Bull. 1993;16(11):1099–1103. DOI: 10.1248/bpb.16.1099.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Линднер Д.П., Поберий И.А., Родкин М.Я., Ефимов В.С. Морфометрический анализ популяции тучных клеток. Архив патологии. 1980;6:60–64.</mixed-citation><mixed-citation xml:lang="en">Линднер Д.П., Поберий И.А., Родкин М.Я., Ефимов В.С. Морфометрический анализ популяции тучных клеток. Архив патологии. 1980;6:60–64.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Иммунологические методы; пер. с нем. А.П. Тарасова; под ред. Г. Фримеля. М.: Медицина, 1987:472.</mixed-citation><mixed-citation xml:lang="en">Иммунологические методы; пер. с нем. А.П. Тарасова; под ред. Г. Фримеля. М.: Медицина, 1987:472.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Носейкина Е.М., Хвостова А.Е., Ларина Т.И., Митрохин Н.М. Базофилы крови морской свинки как тестовая система для оценки противоаллергической активности химических соединений in vitro. Кубанский научный медицинский вестник. 2011;6(129):96–100.</mixed-citation><mixed-citation xml:lang="en">Носейкина Е.М., Хвостова А.Е., Ларина Т.И., Митрохин Н.М. Базофилы крови морской свинки как тестовая система для оценки противоаллергической активности химических соединений in vitro. Кубанский научный медицинский вестник. 2011;6(129):96–100.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Rothschild A.M. Mechanisms of histamine release by compound 48-80. Br. J. Pharmacol. 1970;38(1):253–262. DOI: 10.1111/j.1476-5381.1970.tb10354.x.</mixed-citation><mixed-citation xml:lang="en">Rothschild A.M. Mechanisms of histamine release by compound 48-80. Br. J. Pharmacol. 1970;38(1):253–262. DOI: 10.1111/j.1476-5381.1970.tb10354.x.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Andersson P. Antigen-induced bronchial anaphylaxis in actively sensitized guinea-pigs. Allergy. 1980;35(1):65–71. DOI: 10.1111/j.1398-9995.1980.tb01718.x.</mixed-citation><mixed-citation xml:lang="en">Andersson P. Antigen-induced bronchial anaphylaxis in actively sensitized guinea-pigs. Allergy. 1980;35(1):65–71. DOI: 10.1111/j.1398-9995.1980.tb01718.x.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Seder R.A., Paul W.E., Dvorak A.M., Sharkis S.J., KageySobotka A., Niv Y. et al. Mouse splenic and bone marrow cell populations that express high-affinity Fc epsilon receptors and produce interleukin 4 are highly enriched in basophils. Proc. Natl. Acad. Sci. U S A. 1991;88(7):2835–2839. DOI: 10.1073/pnas.88.7.2835.</mixed-citation><mixed-citation xml:lang="en">Seder R.A., Paul W.E., Dvorak A.M., Sharkis S.J., KageySobotka A., Niv Y. et al. Mouse splenic and bone marrow cell populations that express high-affinity Fc epsilon receptors and produce interleukin 4 are highly enriched in basophils. Proc. Natl. Acad. Sci. U S A. 1991;88(7):2835–2839. DOI: 10.1073/pnas.88.7.2835.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Ikeda R.K., Miller M., Nayar J., Walker L., Cho J.Y., McElwain K. et al. Accumulation of peribronchial mast cells in a mouse model of ovalbumin allergen induced chronic airway inflammation: modulation by immunostimulatory DNA sequences. J. Immunol. 2003;171(9):4860–4867. DOI: 10.4049/jimmunol.171.9.4860.</mixed-citation><mixed-citation xml:lang="en">Ikeda R.K., Miller M., Nayar J., Walker L., Cho J.Y., McElwain K. et al. Accumulation of peribronchial mast cells in a mouse model of ovalbumin allergen induced chronic airway inflammation: modulation by immunostimulatory DNA sequences. J. Immunol. 2003;171(9):4860–4867. DOI: 10.4049/jimmunol.171.9.4860.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Schramm C.M., Puddington L., Wu C., Guernsey L., Gharaee-Kermani M., Phan S.H. et al. Chronic inhaled ovalbumin exposure induces antigen-dependent but not antigen-specific inhalational tolerance in a murine model of allergic airway disease. Am. J. Pathol. 2004;164(1):295–304. DOI: 10.1016/S0002-9440(10)63119-7.</mixed-citation><mixed-citation xml:lang="en">Schramm C.M., Puddington L., Wu C., Guernsey L., Gharaee-Kermani M., Phan S.H. et al. Chronic inhaled ovalbumin exposure induces antigen-dependent but not antigen-specific inhalational tolerance in a murine model of allergic airway disease. Am. J. Pathol. 2004;164(1):295–304. DOI: 10.1016/S0002-9440(10)63119-7.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Brightling C.E., Bradding P., Symon F.A., Holgate S.T., Wardlaw A.J., Pavord I.D. Mast-cell infiltration of airway smooth muscle in asthma. N. Engl. J. Med. 2002;346(22):1699–1705. DOI: 10.1056/NEJMoa012705.</mixed-citation><mixed-citation xml:lang="en">Brightling C.E., Bradding P., Symon F.A., Holgate S.T., Wardlaw A.J., Pavord I.D. Mast-cell infiltration of airway smooth muscle in asthma. N. Engl. J. Med. 2002;346(22):1699–1705. DOI: 10.1056/NEJMoa012705.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Krystel-Whittemore M., Dileepan K.N., Wood J.G. Mast cell: A multi-functional master cell. Front. Immunol. 2016;6:620. DOI: 10.3389/fimmu.2015.00620.</mixed-citation><mixed-citation xml:lang="en">Krystel-Whittemore M., Dileepan K.N., Wood J.G. Mast cell: A multi-functional master cell. Front. Immunol. 2016;6:620. DOI: 10.3389/fimmu.2015.00620.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Дзодзикова М.Э. Особенности дегрануляции и апоптоз тучных клеток. Вестник Российского университета дружбы народов. Серия: Медицина. 2005;1(29):102–107.</mixed-citation><mixed-citation xml:lang="en">Дзодзикова М.Э. Особенности дегрануляции и апоптоз тучных клеток. Вестник Российского университета дружбы народов. Серия: Медицина. 2005;1(29):102–107.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Raveendran V.V., Smith D.D., Tan X., Sweeney M.E., Reed G.A., Flynn C.A. et al. Chronic ingestion of H1-antihistamines increase progression of atherosclerosis in apolipoprotein E-/mice. PLoS One. 2014;9(7):e102165. DOI: 10.1371/journal.pone.0102165.</mixed-citation><mixed-citation xml:lang="en">Raveendran V.V., Smith D.D., Tan X., Sweeney M.E., Reed G.A., Flynn C.A. et al. Chronic ingestion of H1-antihistamines increase progression of atherosclerosis in apolipoprotein E-/mice. PLoS One. 2014;9(7):e102165. DOI: 10.1371/journal.pone.0102165.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Bery A.I., Shepherd H.M., Li W., Krupnick A.S., Gelman A.E., Kreisel D. Role of tertiary lymphoid organs in the regulation of immune responses in the periphery. Cell Mol. Life Sci. 2022;79(7):359. DOI: 10.1007/s00018-022-04388-x.</mixed-citation><mixed-citation xml:lang="en">Bery A.I., Shepherd H.M., Li W., Krupnick A.S., Gelman A.E., Kreisel D. Role of tertiary lymphoid organs in the regulation of immune responses in the periphery. Cell Mol. Life Sci. 2022;79(7):359. DOI: 10.1007/s00018-022-04388-x.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Halle S., Dujardin H.C., Bakocevic N., Fleige H., Danzer H., Willenzon S. et al. Induced bronchus-associated lymphoid tissue serves as a general priming site for T cells and is maintained by dendritic cells. J. Exp. Med. 2009;206(12):2593– 2601. DOI: 10.1084/jem.20091472.</mixed-citation><mixed-citation xml:lang="en">Halle S., Dujardin H.C., Bakocevic N., Fleige H., Danzer H., Willenzon S. et al. Induced bronchus-associated lymphoid tissue serves as a general priming site for T cells and is maintained by dendritic cells. J. Exp. Med. 2009;206(12):2593– 2601. DOI: 10.1084/jem.20091472.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Bradding P., Walls A.F., Holgate S.T. The role of the mast cell in the pathophysiology of asthma. J. Allergy Clin. Immunol. 2006;117(6):1277–1284. DOI: 10.1016/j.jaci.2006.02.039.</mixed-citation><mixed-citation xml:lang="en">Bradding P., Walls A.F., Holgate S.T. The role of the mast cell in the pathophysiology of asthma. J. Allergy Clin. Immunol. 2006;117(6):1277–1284. DOI: 10.1016/j.jaci.2006.02.039.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Williams C.M., Galli S.J. The diverse potential effector and immunoregulatory roles of mast cells in allergic disease. J. Allergy Clin. Immunol. 2000;105(5):847–859. DOI: 10.1067/mai.2000.106485.</mixed-citation><mixed-citation xml:lang="en">Williams C.M., Galli S.J. The diverse potential effector and immunoregulatory roles of mast cells in allergic disease. J. Allergy Clin. Immunol. 2000;105(5):847–859. DOI: 10.1067/mai.2000.106485.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Cairns J.A., Walls A.F. Mast cell tryptase stimulates the synthesis of type I collagen in human lung fibroblasts. J. Clin. Invest. 1997;99(6):1313–1321. DOI: 10.1172/JCI119290.</mixed-citation><mixed-citation xml:lang="en">Cairns J.A., Walls A.F. Mast cell tryptase stimulates the synthesis of type I collagen in human lung fibroblasts. J. Clin. Invest. 1997;99(6):1313–1321. DOI: 10.1172/JCI119290.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Gruber B.L., Kew R.R., Jelaska A., Marchese M.J., Garlick J., Ren S., Schwartz L.B. et al. Human mast cells activate fibroblasts: tryptase is a fibrogenic factor stimulating collagen messenger ribonucleic acid synthesis and fibroblast chemotaxis. J. Immunol. 1997;158(5):2310–2317.</mixed-citation><mixed-citation xml:lang="en">Gruber B.L., Kew R.R., Jelaska A., Marchese M.J., Garlick J., Ren S., Schwartz L.B. et al. Human mast cells activate fibroblasts: tryptase is a fibrogenic factor stimulating collagen messenger ribonucleic acid synthesis and fibroblast chemotaxis. J. Immunol. 1997;158(5):2310–2317.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Garbuzenko E., Nagler A., Pickholtz D., Gillery P., Reich R., Maquart F.X. et al. Human mast cells stimulate fibroblast proliferation, collagen synthesis and lattice contraction: a direct role for mast cells in skin fibrosis. Clin. Exp. Allergy. 2002;32(2):237–246. DOI: 10.1046/j.1365-2222.2002.01293.x.</mixed-citation><mixed-citation xml:lang="en">Garbuzenko E., Nagler A., Pickholtz D., Gillery P., Reich R., Maquart F.X. et al. Human mast cells stimulate fibroblast proliferation, collagen synthesis and lattice contraction: a direct role for mast cells in skin fibrosis. Clin. Exp. Allergy. 2002;32(2):237–246. DOI: 10.1046/j.1365-2222.2002.01293.x.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Nabe T., Matsuya K., Akamizu K., Fujita M., Nakagawa T., Shioe M. et al. Roles of basophils and mast cells infiltrating the lung by multiple antigen challenges in asthmatic responses of mice. Br. J. Pharmacol. 2013;169(2):462–476. DOI: 10.1111/bph.12154.</mixed-citation><mixed-citation xml:lang="en">Nabe T., Matsuya K., Akamizu K., Fujita M., Nakagawa T., Shioe M. et al. Roles of basophils and mast cells infiltrating the lung by multiple antigen challenges in asthmatic responses of mice. Br. J. Pharmacol. 2013;169(2):462–476. DOI: 10.1111/bph.12154.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Miyake K., Ito J., Karasuyama H. Role of basophils in a broad spectrum of disorders. Front. Immunol. 2022;13:902494. DOI: 10.3389/fimmu.2022.902494.</mixed-citation><mixed-citation xml:lang="en">Miyake K., Ito J., Karasuyama H. Role of basophils in a broad spectrum of disorders. Front. Immunol. 2022;13:902494. DOI: 10.3389/fimmu.2022.902494.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Chandler C.E., Ernst R.K. Bacterial lipids: powerful modifiers of the innate immune response. F1000Res. 2017;6:F1000 Faculty Rev-1334. DOI: 10.12688/f1000research.11388.1.</mixed-citation><mixed-citation xml:lang="en">Chandler C.E., Ernst R.K. Bacterial lipids: powerful modifiers of the innate immune response. F1000Res. 2017;6:F1000 Faculty Rev-1334. DOI: 10.12688/f1000research.11388.1.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Krishnaswamy J.K., Jirmo A.C., Baru A.M., Ebensen T., Guzmán C.A., Sparwasser T. et al. Toll-like receptor-2 agonist-allergen coupling efficiently redirects Th2 cell responses and inhibits allergic airway eosinophilia. Am. J. Respir. Cell. Mol. Biol. 2012;47(6):852–863. DOI: 10.1165/rcmb.2011-0414OC.</mixed-citation><mixed-citation xml:lang="en">Krishnaswamy J.K., Jirmo A.C., Baru A.M., Ebensen T., Guzmán C.A., Sparwasser T. et al. Toll-like receptor-2 agonist-allergen coupling efficiently redirects Th2 cell responses and inhibits allergic airway eosinophilia. Am. J. Respir. Cell. Mol. Biol. 2012;47(6):852–863. DOI: 10.1165/rcmb.2011-0414OC.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Velasco G., Campo M., Manrique O.J., Bellou A., He H., Arestides R.S. et al. Toll-like receptor 4 or 2 agonists decrease allergic inflammation. Am. J. Respir. Cell Mol. Biol. 2005;32(3):218–224. DOI: 10.1165/rcmb.2003-0435OC.</mixed-citation><mixed-citation xml:lang="en">Velasco G., Campo M., Manrique O.J., Bellou A., He H., Arestides R.S. et al. Toll-like receptor 4 or 2 agonists decrease allergic inflammation. Am. J. Respir. Cell Mol. Biol. 2005;32(3):218–224. DOI: 10.1165/rcmb.2003-0435OC.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Ma S.Q., Wei H.L., Zhang X. TLR2 regulates allergic airway inflammation through NF-κB and MAPK signaling pathways in asthmatic mice. Eur. Rev. Med. Pharmacol. Sci. 2018;22(10):3138–3146.DOI:10.26355/eurrev_201805_15073.</mixed-citation><mixed-citation xml:lang="en">Ma S.Q., Wei H.L., Zhang X. TLR2 regulates allergic airway inflammation through NF-κB and MAPK signaling pathways in asthmatic mice. Eur. Rev. Med. Pharmacol. Sci. 2018;22(10):3138–3146.DOI:10.26355/eurrev_201805_15073.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Kasakura K., Takahashi K., Aizawa T., Hosono A., Kaminogawa S. A TLR2 ligand suppresses allergic inflammatory reactions by acting directly on mast cells. Int. Arch. Allergy Immunol. 2009;150(4):359–369. DOI: 10.1159/000226237.</mixed-citation><mixed-citation xml:lang="en">Kasakura K., Takahashi K., Aizawa T., Hosono A., Kaminogawa S. A TLR2 ligand suppresses allergic inflammatory reactions by acting directly on mast cells. Int. Arch. Allergy Immunol. 2009;150(4):359–369. DOI: 10.1159/000226237.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Yu Y., Yip K.H., Tam I.Y., Sam S.W., Ng C.W., Zhang W. et al. Differential effects of the Toll-like receptor 2 agonists, PGN and Pam3CSK4 on anti-IgE induced human mast cell activation. PLoS One. 2014;9(11):e112989. DOI: 10.1371/journal.pone.0112989.</mixed-citation><mixed-citation xml:lang="en">Yu Y., Yip K.H., Tam I.Y., Sam S.W., Ng C.W., Zhang W. et al. Differential effects of the Toll-like receptor 2 agonists, PGN and Pam3CSK4 on anti-IgE induced human mast cell activation. PLoS One. 2014;9(11):e112989. DOI: 10.1371/journal.pone.0112989.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang Y.Y., Yu Y.Y., Zhang Y.R., Zhang W., Yu B. The modulatory effect of TLR2 on LL-37-induced human mast cells activation. Biochem. Biophys. Res. Commun. 2016;470(2):368– 374. DOI: 10.1016/j.bbrc.2016.01.037.</mixed-citation><mixed-citation xml:lang="en">Zhang Y.Y., Yu Y.Y., Zhang Y.R., Zhang W., Yu B. The modulatory effect of TLR2 on LL-37-induced human mast cells activation. Biochem. Biophys. Res. Commun. 2016;470(2):368– 374. DOI: 10.1016/j.bbrc.2016.01.037.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
